Joseph J. Eron, MD
Co-Director, Clinical Trials Unit (CTU)
Director, CFAR Clinical Core
Chief, Division of Infectious Diseases
Herman and Louise Smith Distinguished Professor of Medicine
Areas of Interest
Antiretroviral therapy, resistance, pharmacology, transmission and HIV persistence and disruption of latency
About
Dr. Eron is Principal Investigator of the HIV/AIDS Clinical Research Unit at UNC-CH and Director of the Clinical Core for the UNC Center for AIDS Research (CFAR). He has been part of the AIDS Clinical Trials Group since 1993 and has held multiple leadership positions including Chair of the Optimization of ART Committee and the Cure Transformative Science Group. He is the Principal Investigator of the UNC Clinical trials Unit with sites in Chapel Hill, Greensboro, Lilongwe, Malawi and Hanoi, Vietnam. In addition, he is a leader of the UNC Acute HIV Infection research team and a collaborator in the UNC HIV Cure Center. Over the last 15 years, Dr. Eron has led the development of the UNC HIV CFAR clinic cohort that includes over 5,000 HIV infected individuals and has active collaboration and membership in the NA ACCORD and CNICS cohorts. Dr. Eron has over 400 publications in peer-reviewed journals focusing on antiretroviral therapy, resistance, pharmacology, transmission and HIV persistence, and disruption of latency. Recent work has included publications from the UNC-CFAR HIV Clinical Cohort, the ACTG, HPTN and IAS-USA HIV treatment guidelines in JAMA, 2020. Dr. Eron has worked extensively in the area of HIV drug development and led or participated in original studies of many antiretroviral therapies. He also continues as an active HIV infectious disease clinician. He is now the leader of the ACTG Scientific Agenda Steering Committee and is Vice Chair (co-PI) of the ACTG network.
In the news
The National Institutes of Health held a congressional briefing July 9 at the Dirksen Senate Office Building in Washington, DC. Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases, and Dr. Joe Eron, chief of infectious diseases, kicked off the briefing session with an overview of HIV treatment and prevention research, recognizing … Read more There’s a new tool to help prevent HIV in people who are at risk of contracting the virus, and health experts say it has the potential to change the trajectory of the global epidemic and may be especially beneficial for some older adults. In June, the U.S. Food and Drug Administration (FDA) approved the twice-yearly … Read more Hospitalization causes among persons with HIV (PWH) have shifted to non-AIDS conditions, but the complete disease profile of hospitalized PWH has not been well described. To inform hospitalization and readmission prevention efforts, Thibaut Davy-Mendez, PhD, MSPH, Sonia Napravnik, PhD, and Joseph J. Eron, MD, examined non-AIDS disease prevalence among PWH hospitalized in 4 US cohorts and 1 Canadian … Read more As HIV care improves, people with Aids are now hospitalized more for non-AIDS conditions. Despite this, the complete disease profile of hospitalized people with HIV has not been well described. To inform hospitalization and readmission prevention efforts, researchers with the institute examined non-AIDS disease prevalence among PWH hospitalized in 4 US cohorts and 1 Canadian … Read more
Eron, Cohen Lead NIH Congressional Briefing on HIV Treatment and Prevention Research
What Older Adults Need to Know About a New HIV Medication
Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With (HIV) in the United States and Canada, 2008–2018
Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With Human Immunodeficiency Virus (HIV) in the United States and Canada, 2008–2018
-
Undergraduate
Harpur College
-
Medical School
Harvard Medical School
-
Residency
Massachusetts General Hospital, Harvard Medical School
-
Fellowship
Massachusetts General Hospital, Harvard Medical School